Autor: MHorn

  • Post-harvest and Systems Technician

    Join our growing team Welcome to Avextra, where our mission is to understand and use the therapeutic potential of cannabis-based medicines to improve the quality of patients‘ lives. We are a team of talented and dedicated individuals working towards this vision, and we are always looking for qualified and highly motivated individuals to join us…

  • International Regulatory Affairs Manager

    (temporary replacement during 12 months due to parental leave) The International Regulatory Affairs Manager is responsible within Avextra Pharma GmbH for the compilation of regulatory documents for new products. To this end, the International Regulatory Affairs Manager collaborates on all measures necessary to obtain approval from international authorities for the development, manufacture, marketing, and distribution…

  • Quality Assurance Manager / QA-Manager GCP (m/w/d)

    Ab sofort bzw. zum nächstmöglichen Zeitpunkt in Vollzeit oder Teilzeit Die Avextra Pharma GmbH ist eines der führenden unabhängigen europäischen Unternehmen im Bereich Medizinalcannabis (von Anbau, zu Produktion und Forschung). Dabei stehen für uns höchste Qualität in Produkt und Prozess sowie ein partnerschaftlicher Ansatz im Vordergrund. Unser Standort in Bensheim ist die zentrale Schnittstelle für…

  • Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

    Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

    BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will…

  • (Senior) Investor Relations Director (m/w/d)

    Full-time / part-time as soon as possible – in Berlin or Rein-Main area and home office Avextra is a German research-based biopharmaceutical company focused on developing life-changing, regulator approved medicines derived from the cannabis plant. Our product candidates have the potential to improve the quality of life for terminally ill patients and their loved ones.…

  • Medical Affairs Manager (m/w/d)

    As a Medical Affairs Manager, you will play a pivotal role in bridging the gap between the medical and commercial aspects of our organization. This position involves collaborating with various stakeholders, including internal teams, healthcare professionals, and regulatory bodies, to ensure the successful integration of medical strategies into overall business goals. You will be responsible…

  • Senior R&D Scientist (m/w/d)

    Ab sofort zum nächstmöglichen Zeitpunkt in Vollzeit / vollzeitnahe Teilzeit – in Bensheim und im Homeoffice Werde Teil eines globalen, internationalen Teams das innovative Arzneimittel aus der Cannabispflanze herstellt und für die behördliche Zulassung entwickelt. Wir sind ein schnell wachsendes Start-Up im spannenden GMP-Umfeld mit Standorten in Bensheim, Berlin und Portugal. Gestalte als Teil des…

  • Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

    Mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

    Bensheim, 23.01.2024 – Erste Studien zeigen, dass neuropathische Schmerzformen, wie CINP, eine vielversprechende Indikation für den Nutzen von CBMs darstellen könnten. Jedoch fehlt – wie so oft in der Cannabis Medizin – eine belastbare Evidenz für diese sensible Patientengruppe. Die Deutsche Gesellschaft für Schmerzmedizin e.V. (DGS) und der forschungsorientierte Hersteller von Cannabis-basierten Arzneimitteln Avextra adressieren…

  • German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

    German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN

    Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce a joint study with the German Pain Association (DGS) focused on chemotherapy-induced neuropathic pain (CINP).

  • AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

    AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU

    Lisbon, January 17th, 2024 – Avextra, the leading German manufacturer of cannabis-based medicines, has entered a strategic, long-term partnership with the Instituto Universitário de Ciências da Saúde-Cooperativa de Ensino Superior Politécnico e Universitário (IUCS-CESPU) focused on Research & Development (R&D) of regulator approved medicines based on the cannabis plant.

DE